MEDP Beats Peers by 4 Points, But the CEO Keeps Selling

MEDP gained 7.4% over the past week, more than double the median 3.0% advance for its closest peers, reaching $662.48, yet the dominant fact in the setup remains unchanged: founder-CEO August Troendle sold just over $31 million of stock across four sessions in late September at prices between $620 and $625, none of it under a pre-arranged 10b5-1 plan. Net insider selling over the past 90 days totals roughly $208 million. Troendle's latest Schedule 13D amendment, filed September 28, shows his stake trimmed to 19.1% from 20.0%. The 13D designation means he holds more than 5% with a disclosed intent; stakes are as last disclosed, and a holder dropping below 5% can exit without a further filing.

The analyst community has moved in the opposite direction from Troendle. UBS was the most significant mover in the recent stretch, upgrading to Neutral from Sell on September 30 and lifting its target sharply to $673 from $405. Mizuho, already Outperform, raised its target to $700 on October 7. The mean price target across the Street now sits at $596, which is below the current price at $662, suggesting the consensus has not fully caught up with the stock's recent move. The bull case rests on accelerating request-for-proposals, half of Q2 bookings from oncology, and management's expectation that gross and net bookings improve from Q2 levels through year-end. The bear case is structural: heavy exposure to small and midsize biotech customers leaves bookings vulnerable to capital-market weakness and FDA funding disruptions, and the stock's current P/E of roughly 35x leaves limited room for a stumble.

T. Rowe Price stands out on the institutional side, adding 1.78 million shares in the quarter ending September 30 to build a 7.4% stake, a meaningful vote of confidence that runs counter to the CEO's direction of travel. BlackRock, Vanguard, and State Street all added modestly. The lending market itself signals no particular stress: borrow availability is running at more than 6,600% of short interest, meaning shares available to lend outnumber shares currently borrowed by a factor of roughly 66 to one. Short interest has unwound about 9% over the past month to 5.4% of free float, and borrowing costs at 0.35% remain negligible. Put/call ratio at 2.20 is nearly two standard deviations below its 20-day average of 2.52, a shift toward less defensive options positioning even as the stock has pushed above previous analyst targets.

Today's Q3 print will test whether the bookings acceleration management flagged for the second half of 2026 has materialised in a way that justifies a price already above the Street's average target, while the market digests the continued gap between what the CEO is doing with his shares and what institutional buyers are doing with theirs.